Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
You may also be interested in...
AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab for cancer and benralizumab for asthma are among important milestones ahead.
The U.K. drug maker flaunted its dramatically improved pipeline to investors Nov. 18, highlighting oncology specifically, a new “growth platform.” But will investors be persuaded to wait three years for growth?
Stakeholders are asking if AstraZeneca remains committed to neglected tropical diseases after the company announces it will close its Indian research unit. The center was the last remaining big pharma basic research center in India.